Search Press releases Keywords From To 22 Apr 2024 UCB receives European Commission approval for BIMZELX[®]▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa Read More 19 Apr 2024 Acquisition of own shares Read More 17 Apr 2024 FINTEPLA[®]▼ (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) Read More 12 Apr 2024 Acquisition of own shares Read More 12 Apr 2024 Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY[®]▼ (romosozumab) can help to close the treatment gap in osteoporosis Read More 12 Apr 2024 UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting Read More Pagination First page Previous page Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe